v3.25.4

Net loss per share | 9 Months Ended
--- | ---
Dec. 31, 2025
Earnings Per Share [Abstract] |
Net loss per share | Net loss per share Basic and diluted net loss per share attributable to common stockholders was calculated as follows:
| Three Months Ended December 31, |  | Nine Months Ended December 31,
| 2025 |  | 2024 |  | 2025 |  | 2024
Numerator: |  |  |  |  |  |  |
Net loss | $ | (70,930) |  |  | $ | (66,340) |  |  | $ | (240,723) |  |  | $ | (173,167) |
Denominator: |  |  |  |  |  |  |
Weighted average common shares outstanding, basic and diluted | 92,187,581 |  |  | 83,498,892 |  |  | 91,874,481 |  |  | 77,113,695 |
Net loss per share, basic and diluted | $ | (0.77) |  |  | $ | (0.79) |  |  | $ | (2.62) |  |  | $ | (2.25) |
The 14,058,153 shares of the Company's common stock issuable upon exercise of pre-funded warrants described in Note 9 to these condensed consolidated financial statements are included as outstanding common stock in the calculation of basic and diluted net loss per share. The Company’s potentially dilutive securities, which include stock options, unvested restricted and performance stock units and warrants to purchase shares of common stock that resulted from the conversion of warrants to purchase shares of series seed preferred stock existing before the Company's IPO, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:
| Three and Nine Months Ended December 31,
| 2025 |  | 2024
Options to purchase common stock | 11,927,970 |  |  | 10,213,861 |
Unvested restricted and performance stock units | 5,663,023 |  |  | 3,491,335 |
Warrants to purchase common stock | — |  |  | 497,344 |
| 17,590,993 |  |  | 14,202,540 |

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration